Global Personalized Cancer Medicine Supply, Demand and Key Producers, 2023-2029

Global Personalized Cancer Medicine Supply, Demand and Key Producers, 2023-2029

The global Personalized Cancer Medicine market size is expected to reach $ 366720 million by 2029, rising at a market growth of 12.0% CAGR during the forecast period (2023-2029).

In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.

Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.

Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.

Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.

This report studies the global Personalized Cancer Medicine demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Personalized Cancer Medicine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Personalized Cancer Medicine that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Personalized Cancer Medicine total market, 2018-2029, (USD Million)

Global Personalized Cancer Medicine total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Personalized Cancer Medicine total market, key domestic companies and share, (USD Million)

Global Personalized Cancer Medicine revenue by player and market share 2018-2023, (USD Million)

Global Personalized Cancer Medicine total market by Method, CAGR, 2018-2029, (USD Million)

Global Personalized Cancer Medicine total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Personalized Cancer Medicine market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca and Merck & Co, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Personalized Cancer Medicine market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Method, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Personalized Cancer Medicine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Personalized Cancer Medicine Market, Segmentation by Method
Cancer Immunotherapy
Targeted Therapy

Global Personalized Cancer Medicine Market, Segmentation by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other

Companies Profiled:
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine

Key Questions Answered

1. How big is the global Personalized Cancer Medicine market?

2. What is the demand of the global Personalized Cancer Medicine market?

3. What is the year over year growth of the global Personalized Cancer Medicine market?

4. What is the total value of the global Personalized Cancer Medicine market?

5. Who are the major players in the global Personalized Cancer Medicine market?